Last 12 months
Inside the activity.
11 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 2 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 3 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 787 | $2.95 | $2,321.65 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 22,963 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · derivative · entry 8 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,037 Underlying: Common Stock, par value $0.0001 · 22,963 shares Expires 2029-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 4,019 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock, par value $0.0001 · 4,019 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
SaleCommon Stock, par value $0.0001 | 26,982 | $12.00 | $323,784.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 22,963 | $2.95 | $67,740.85 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 4,019 | $2.60 | $10,449.40 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:17 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $11.70 | $35,181.90 |
DisclosureSEC source: 0001104659-22-076849 · tm2220259-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,811 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 5,462 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,769 Underlying: Common Stock, par value $0.0001 · 5,462 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC |
Roberts M ScotChief Scientific Officer
|
SaleCommon Stock, par value $0.0001 | 5,462 | $12.00 | $65,546.18 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0050, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 5,462 | $2.60 | $14,201.20 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 11,769 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,231 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 25,583 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,817 Underlying: Common Stock, par value $0.0001 · 61,400 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC |
Roberts M ScotChief Scientific Officer
|
SaleCommon Stock, par value $0.0001 | 37,352 | $12.00 | $448,253.88 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0250, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 11,769 | $2.60 | $30,599.40 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 25,583 | $1.92 | $49,152.62 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC |
Jorkasky DianeDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 17,610 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · derivative · entry 3 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 Underlying: Common Stock, par value $0.0001 · 40,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC |
Jorkasky DianeDirector
|
SaleCommon Stock, par value $0.0001 | 17,610 | $11.75 | $206,943.92 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · nonDerivative · entry 2 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $11.88, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC |
Jorkasky DianeDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 17,610 | $3.15 | $55,471.50 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · nonDerivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 60 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 6 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 60 shares Expires 2022-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F1 · shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F1 · derivative.underlying_shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 159 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 5 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 159 shares Expires 2022-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 4,775 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 60 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · derivative · entry 4 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 60 shares Expires 2022-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F1 · shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F1 · derivative.underlying_shares: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 60 | $2.40 | $144.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 3 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 159 | $2.40 | $381.60 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 2 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 20:10 UTC |
Schafer KlausDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 60 | $2.40 | $144.00 |
DisclosureSEC source: 0001104659-22-073497 · tm2219109-1_4seq1.xml · nonDerivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:27 UTC |
Drutz DavidDirector
|
PurchaseCommon Stock, par value $0.0001 | 1,000 | $8.00 | $8,000.00 |
DisclosureSEC source: 0001104659-22-072059 · tm2218746d1_4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,012 Read SEC document |
| May 30, 2022 Filed May 31, 2022 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $5.03 | $15,130.24 |
DisclosureSEC source: 0001104659-22-066739 · tm2217376-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,818 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| May 24, 2022 Filed May 25, 2022 19:00 UTC |
Drutz DavidDirector
|
PurchaseCommon Stock, par value $0.0001 | 1,200 | $4.50 | $5,400.00 |
DisclosureSEC source: 0001104659-22-064786 · tm2216827-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,012 Read SEC document |
| April 30, 2022 Filed May 2, 2022 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $4.52 | $13,596.16 |
DisclosureSEC source: 0001104659-22-054853 · tm2214195-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,826 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $6.05 | $18,192.35 |
DisclosureSEC source: 0001104659-22-041223 · tm2211105-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,834 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 00:01 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $7.41 | $22,281.87 |
DisclosureSEC source: 0001104659-22-028856 · tm228070d1_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,841 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionStock Options (option to buy) · Derivative | 30,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · derivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC |
Harris Matthew ScottChief Medical Officer
|
SaleCommon Stock, par value $0.0001 | 30,000 | $7.52 | $225,600.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,545 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:00 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 30,000 | $1.92 | $57,639.00 |
DisclosureSEC source: 0001104659-22-029462 · tm228203-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 31,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 6 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock, par value $0.0001 · 31,100 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
GrantStock Options (option to buy) · Derivative | 91,600 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,600 Underlying: Common Stock, par value $0.0001 · 91,600 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
GrantRestricted Stock Units · Derivative | 75,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 6 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,800 Underlying: Common Stock, par value $0.0001 · 75,800 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
GrantStock Options (option to buy) · Derivative | 223,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,000 Underlying: Common Stock, par value $0.0001 · 223,000 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:55 UTC |
Roberts M ScotChief Scientific Officer
|
GrantRestricted Stock Units · Derivative | 31,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock, par value $0.0001 · 31,100 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:55 UTC |
Roberts M ScotChief Scientific Officer
|
GrantStock Options (option to buy) · Derivative | 91,600 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,600 Underlying: Common Stock, par value $0.0001 · 91,600 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $7.98 | $17,420.34 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,545 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,636 Underlying: Common Stock, par value $0.0001 · 16,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 7,655 | $7.98 | $61,086.90 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,848 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionCommon Stock, par value $0.0001 | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC |
Roberts M ScotChief Scientific Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $7.98 | $17,420.34 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2022 Filed Feb 4, 2022 00:56 UTC |
Harris Matthew ScottChief Medical Officer
|
GrantCommon Stock, par value $0.0001 | 1,800 | $6.86 | $12,348.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,562 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 4, 2022 00:56 UTC |
Garg Vipin KDirector · President and CEO
|
GrantCommon Stock, par value $0.0001 | 2,757 | $6.86 | $18,913.02 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,958 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.